Submitted by sandy craine on Fri, 12/12/2008 - 12:32pm
Why Gleevec-type Drugs Control, But Do Not Eradicate, Leukemia
ScienceDaily (Dec. 11, 2008) — Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.
Why Gleevec-type Drugs Control, But Do Not Eradicate, Leukemia
ScienceDaily (Dec. 11, 2008) — Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.
Submitted by sandy craine on Fri, 12/12/2008 - 12:27pm
New Approach To Help Control Drug Resistance In Leukemia Identified
ScienceDaily (Mar. 25, 2008) — Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).
New Approach To Help Control Drug Resistance In Leukemia Identified
ScienceDaily (Mar. 25, 2008) — Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).
Submitted by sandy craine on Fri, 12/12/2008 - 12:20pm
Combination Of Two Novel Anti-cancer Agents May Help Fight CML Resistant To Current Therapy
ScienceDaily (June 1, 2008) — Virginia Commonwealth University Massey Cancer Center researchers have identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy.
Combination Of Two Novel Anti-cancer Agents May Help Fight CML Resistant To Current Therapy
ScienceDaily (June 1, 2008) — Virginia Commonwealth University Massey Cancer Center researchers have identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy.
Submitted by sandy craine on Fri, 12/12/2008 - 12:14pm
Drug Shown To Be Clinically Active Against Multiple Target Mutations In Two Types Of Leukemia And Myeloproliferative Disorders
ScienceDaily (Dec. 21, 2006) — Researchers at The University of Texas M. D. Anderson Cancer Center report that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients.
Drug Shown To Be Clinically Active Against Multiple Target Mutations In Two Types Of Leukemia And Myeloproliferative Disorders
ScienceDaily (Dec. 21, 2006) — Researchers at The University of Texas M. D. Anderson Cancer Center report that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients.
Submitted by sandy craine on Fri, 12/12/2008 - 12:07pm
Vaccine Improves Event-free Survival For Leukemia Patients
ScienceDaily (Dec. 11, 2007) — Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.
Vaccine Improves Event-free Survival For Leukemia Patients
ScienceDaily (Dec. 11, 2007) — Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.
Submitted by sandy craine on Fri, 12/12/2008 - 12:03pm
Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For Chronic Myelogenous Leukemia
ScienceDaily (Dec. 10, 2007) — Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.
Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For Chronic Myelogenous Leukemia
ScienceDaily (Dec. 10, 2007) — Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.
Submitted by sandy craine on Fri, 28/11/2008 - 11:50am
4 Nov 2008 : Column 131
NHS Patients (Access to Medicines)
4.7 pm
4 Nov 2008 : Column 131
NHS Patients (Access to Medicines)
4.7 pm
Submitted by sandy craine on Wed, 26/11/2008 - 7:56pm
EUTOS.
Submitted by sandy craine on Sun, 09/11/2008 - 1:51pm
NCCN 3rd Annual Congress: Hematologic Malignancies -- Chronic Myelogenous Leukemia
Combating Progressive Disease by Monitoring and Early Detection: War and PCR (Slides with Transcript)
Jerald P. Radich, MD
NCCN 3rd Annual Congress: Hematologic Malignancies -- Chronic Myelogenous Leukemia
Combating Progressive Disease by Monitoring and Early Detection: War and PCR (Slides with Transcript)
Jerald P. Radich, MD
Submitted by sandy craine on Fri, 07/11/2008 - 4:52pm
1: Leukemia. 2008 Jun;22(6):1191-9. Epub 2008 Apr 3. Links
1: Leukemia. 2008 Jun;22(6):1191-9. Epub 2008 Apr 3. Links
Pages